Frontline Daratumumab Triplet Approved in EU for Transplant-Ineligible Myeloma

November 19, 2019 – The European Commission has approved the triplet regimen of daratumumab with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The approval, which follows a positive opinion granted in October 2019 by the European Medicines Agency’s Committee for Medicinal Products for Human Use, is based on findings from the phase III … (leggi tutto)